Cabg clinical trials

Explore recruiting cabg clinical trials.

Recruiting cabg studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Cabg trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A 26-Week (with 26 Week Extension) Randomized, Multi-Center, Double-Blind Phase 2 Study to Evaluate the Efficacy and Safety of XC001 Gene Therapy as an Adjunct to Coronary Artery Bypass Graft Surgery for Patients with Symptomatic Coronary Artery Disease with Left Ventricular Dysfunction at Risk for Incomplete Revascularization

Netherlands, Germany, Hungary, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

Glutamate infusion for prevention of Acute Kidney Injury in surgery for ischemic heart disease: (GLUTAMICS III = GLUTAmate for Metabolic Intervention in Coronary Surgery III)

Sweden

Therapeutic confirmatory (Phase III) EU CTIS Study details

SGLT2 inhibitor TrEatment iN patients awaiting cOronary arTery bYpass surgery to reduce Post-opErative atrial fibrillation and kidney injury (STENOTYPE trial).

Denmark, Sweden, Czechia

Therapeutic confirmatory (Phase III) EU CTIS Study details

Comparing high and lOw-dose asPirin with dual anTIplatelet therapy for three Months using prasUgrel and aSpirin following Coronary Artery Bypass Grafting. (OPTIMUS-CABG trial).

Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Anticoagulation for New-Onset Post-Operative Atrial Fibrillation after CABG - PACeS

Germany

Therapeutic use (Phase IV) EU CTIS Study details

Dual Antithrombotic Therapy with Dabigatran and Ticagrelor in Patients with Acute Coronary Syndrome and Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention (ADONIS-PCI)

Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Cabg trials by city

Cabg in Toronto Cabg in Vancouver Cabg in Montreal Cabg in Calgary Cabg in Edmonton Cabg in Ottawa Cabg in Winnipeg Cabg in Quebec City Cabg in Hamilton Cabg in Kitchener Cabg in London Cabg in Halifax Cabg in New York Cabg in Los Angeles Cabg in Chicago Cabg in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease